Examining the topline results from the Phase 2b FRONTIER 1 clinical trial of Johnson & Johnson's JNJ-2113 in patients with Plaque Psoriasis.

Executed on:Jul 13, 2023 11:00 AM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Boston University School of Medicine and Boston Medical Center Associate Professor of Dermatology; Director of the Boston University Center for Ethnic Skin and Founder of the Cosmetic and Laser Center at Boston Medical Center
Treats 50 patients with hidradenitis suppurativa
Specializes in research for skin of color dermatology and pigmentary disorders, with expertise in conditions such as melasma, vitiligo, and post-inflammatory hyperpigmentation. Leads clinical research and trials focused on novel therapies and laser technologies

Interview Goal

This call will discuss the standard of care and the potential of JNJ-2113, an oral interleukin-23 receptor (IL-23R) antagonist peptide being developed by Johnson & Johnson including the Phase 2b FRONTIER 1 clinical trial of Johnson & Johnson's JNJ-2113 in patients with Plaque Psoriasis.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.